Utilizing devTOXqP in a Combined Testing Approach for Identifying Developmental Toxicity Liability of Chemicals [Webinar, 2016 – Slides]

Why develop devTOX? Reduce prevalence of birth defects and decrease animal testing. Our approach represents a unique opportunity to screen compound safety using a human endpoint. devTOX quickPredictTM is a predictive, targeted biomarker assay. (devTOX DiscoveryTM, on the other hand, is a predictive, untargeted metabolomics assay.) Jessica Palmer presented this webinar in October 2016. If you would like to have her go over these slides with you, email gwentling@stemina.com to set up an appointment.

Utilizing devTOXqPTM in a Combined Testing Approach for Identifying Developmental Toxicity Liability of Chemicals

[pardot-form id=”935″ title=”Webinar Slides – Utilizing devTOXqP in a Combined Testing Approach … (October 2016)”]